top of page

The Pink Study

The Pink Study is a clinical study evaluating SpotitEarly’s breath test for breast cancer, led by the Hennessy Institute at Hackensack Meridian Health in New Jersey.

Enrollment is open, access the form below.

Lucid

About the Study

The Pink Study is a multicenter, double-blind observational study planned to include 2,000 participants, with up to 500 women enrolling at Hackensack Meridian Health.

Researchers compare each participant’s breath test result with the result of her mammogram or biopsy to measure how accurately the test detects breast cancer. Because the study is double-blind, neither participants nor researchers know the breath test results while the study is underway.

What participants do

Taking part adds only a few minutes to an appointment you already have. You breathe into a collection mask for three minutes and complete a short survey. There are no needles and nothing invasive, and your mammogram, ultrasound, MRI or biopsy goes ahead as planned.

How the breath test works

The mask is sealed in a container and sent to SpotitEarly’s CLIA-certified laboratory. There, trained detection dogs screen the sample for volatile organic compounds (VOCs) linked to cancer. Our LUCID Bio-AI Hybrid platform monitors the dogs’ responses, including body language and heart rate, and combines them with a chemical analysis of the sample to produce a single result.

Who Can Join

Enrolling

The Pink Study is currently open to participants residing in New Jersey only through our partnership with The Hennessy Institute at Hackensack Meridian Health. We are seeking women who are either due for their annual breast cancer screening (mammogram, ultrasound, or MRI) or are scheduled for a breast biopsy.

All clinical studies are conducted under the oversight of an Institutional Review Board (IRB) to ensure participant safety and adherence to the highest ethical research standards.

If you meet these criteria and would like more information on how to participate, please contact the Hennessy Institute research team at HICAPResearch@hmhn.org.

Click the button below to access the enrollment form.

This study represents a new frontier in cancer prevention.

Elias Obeid, MD

Medical Director, Hennessy Institute for Cancer Prevention and Applied Molecular Medicine, Hackensack Meridian Health

Partnership Acknowledgement

The Pink Study

SpotitEarly is proud to partner with The Hennessy Institute at Hackensack Meridian Health on a new research study in New Jersey for early breast cancer detection. For more information on how to participate, please contact the Hennessy Institute research team at HICAPResearch@hmhn.org .

HICAP Official Logo

The Hennessy Institute at Hackensack Meridian Health

The Rainbow Study was SpotitEarly’s first clinical trial, demonstrating 94% sensitivity and specificity in detecting multiple cancers from a simple breath sample.

bottom of page